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Alexander Vonbank1,2,3†, Christoph H Saely1,2,3†, Philipp Rein1,2,3 and Heinz Drexel1,2,3,4*Abstract
Objective: Insulin resistance (IR) is the key feature of the metabolic syndrome (MetS); its association with peripheral
arterial disease (PAD) is unclear. We hypothesized that IR is associated with both the MetS and sonographically
proven PAD.
Methods: IR was determined by the Homeostasis Model Assessment (HOMA) index in 214 patients with
sonographically proven PAD as well as in 197 controls, who did not have a history of PAD and in whom coronary
artery disease was ruled out angiographically; the MetS was defined according to NCEP-ATPIII criteria.
Results: HOMA IR scores were significantly higher in MetS patients than in subjects without the MetS (5.9 ± 6.2 vs.
2.9 ± 3.9; p <0.001). However, HOMA IR did not differ significantly between patients with PAD and controls
(4.2 ± 5.4 vs. 3.3 ± 4.3; p = 0.124). When both, the presence of MetS and of PAD were considered, HOMA IR was
significantly higher in patients with the MetS both among those with PAD (6.1 ± 5.7 vs. 3.6 ± 5.2; p<0.001) and
among controls (5.8 ± 6.8 vs. 2.3 ± 1.8; p <0.001), whereas it did not differ significantly between patients with PAD
and controls among patients with the MetS (5.8 ± 6.8 vs. 6.1 ± 5.7; p = 0.587) nor among those without the MetS
(2.3 ± 1.8 vs. 3.6 ± 5.2; p = 0.165). Similar results were obtained with the International Diabetes Federation definition
of the MetS.
Conclusion: IR is significantly associated with the MetS but not with sonographically proven PAD.
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The metabolic syndrome (MetS), a cluster of cardiovascu-
lar risk factors including central adiposity, hypertension,
dyslipidemia and impaired glucose metabolism has been
consistently associated with an increase in the incidence
of coronary heart disease, stroke, and cardiovascular mor-
tality [1-7].
Pathophysiologically, insulin resistance is considered the
key feature of the MetS [8]. Indeed, insulin resistance is
associated with all component features of the MetS [9-12].
In epidemiological studies, insulin resistance typically* Correspondence: vivit@lkhf.at
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reproduction in any medium, provided the oris quantified by the Homeostasis Model Assessment
(HOMA) index. We could previously show that HOMA
insulin resistance is associated with the MetS but not with
coronary artery disease (CAD) [13].
Peripheral arterial disease (PAD) is another important
manifestation of systemic atherosclerosis which confers
significant cardiovascular morbidity and mortality [14].
Indeed, the prognosis of PAD patients in general is
worse to that of CAD patients [15]. However, risk factors
for PAD have not been as thoroughly investigated as risk
factors for CAD.
Whereas type 2 diabetes is a well established major
risk factor for PAD [16], only very limited data available
on the association between the MetS and PAD [17-21].
In particular, the role of insulin resistance in PAD is
unclear. Because PAD causes skeleton muscle ischemia,
the ischemic muscle could be a link to insulin resistanceal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.







Aspirin (%) 65.9 54.3 0.005
Clopidogrel (%) 29.0 4.9 <0.001
Metformin (%) * 18.4 28.9 <0.001
Sulfonyrea (%) * 13.8 17.8 0.775
Glitazone (%) * 1.0 1.4 0.689
Insulin (%) * 7.9 5.1 0.211








Angiotensin II Receptor Blocking
Agents (%)
11.2 6.1 0.067
PAD denotes peripheral artery disease.
* Percentage of subjects with type 2 diabetes (n = 87 and 45 in the PAD and
in the control group, respectively).
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lin resistance.
In the present study, we therefore determined HOMA
insulin resistance in a cohort of sonographically charac-
terized PAD patients and in controls without signs or
symptoms of PAD, in whom in addition CAD was ruled
out angiographically. We hypothesized that insulin resist-
ance is associated with both sonographically determined
PAD and with the MetS.
Patients and methods
Study subjects
From August 2007 through December 2010 we enrolled
214 consecutive Caucasian patients with intermittent
claudication who were referred for the evaluation of
established or suspected PAD to the Angiology Clinic at
the Academic Teaching Hospital Feldkirch, a tertiary care
centre in western Austria (state of Vorarlberg). This is the
only angiologic clinic in Vorarlberg; patients typically are
referred to there by general practitioners or specialists in
internal medicine. Assessments regarding the diagnosis of
PAD were part of the common clinical examination; meta-
bolic assessments including the measurement of insulin
resistance were part of the study protocol. Patients were
instructed to fast overnight when they arranged their
appointment to the angiologic clinic.
As controls, we used a cohort of 197 patients in whom
CAD was ruled out angiographically and who had no
PAD. Both PAD patients and controls were enrolled in a
consecutive manner. Patients with type 1 diabetes were
not enrolled; no other exclusion criteria did apply. The
Ethics Committee of the University of Innsbruck approved
the present study, and all participants gave written in-
formed consent.
Information on conventional vascular risk factors was
obtained by a standardized interview; and systolic/diastolic
blood pressure was measured by the Riva–Rocci method
under resting conditions in a sitting position at the day of
hospital entry at least 5 h after the hospitalization for
planned coronary angiography in our control group and
prior to the angiologic examination in our patients with
PAD. Hypertension was defined according to the Seventh
Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood
Pressure [23], and type 2 diabetes mellitus (T2DM) was
diagnosed according to World Health Organization
criteria [24]. Height and weight were recorded, and
body mass index (BMI) was calculated as body weight
(kg)/height (m)2. Table 1 shows pre-existing medication
in PAD cases and in controls.
According to National Cholesterol Education Programme
ATP-III criteria [25] (NCEP – ATPIII), the MetS was di-
agnosed in the presence of any three of: waist circum-
ference >102 cm in men and >88 cm in women,triglycerides ≥150 mg/dl (1.7 mmol/l), high density lipo-
protein (HDL) cholesterol <40 mg/dl (1.0 mmol/l) in
men and <50 mg/dl (1.3 mmol/l) in women, blood pres-
sure ≥130/ ≥85 mmHg, or fasting glucose ≥100 mg/dl
(5.6 mmol/l). Using International Diabetes Federation
(IDF) criteria [26], the MetS was diagnosed in patients
who had a large waist circumference (≥94 cm in men
and ≥80 cm in women) plus any two of: triglycerides
≥150 mg/dl (1.7 mmol/l) or specific treatment for this
lipid abnormality, HDL cholesterol <40 mg/d (1.0 mmol/l)
in males and <50 mg/dl (1.3 mmol/l) in females or specific
treatment for this lipid abnormality, systolic blood pres-
sure ≥130 or diastolic blood pressure ≥85 mmHg or treat-
ment of previously diagnosed hypertension, and fasting
plasma glucose ≥100 mg/dl (5.6 mmol/l) or previously di-
agnosed T2DM.
For Ultrasound examination we used a Philips iU22
ultrasound system. PAD was diagnosed by direct
visualization of atherosclerotic plaques in peripheral ar-
teries of the lower limbs. The scanning protocol in-
cluded a completed lower limb sonography (we scanned
bilateterally the Aa. illiaca ext., Aa. fem. com., Aa. fem.
sup., Aa. fem. prof., Aa. popl., Aa. tib. ant., Aa. tib. post.
and Aa. Brach., respectively). PAD was defined as any
sonographically detectable atherosclerosis in peripheral
arteries [27]. All patients in the PAD group had at least
one stenosis of more than 50% of at least one of these ar-
teries. Coronary angiography in controls was performed
with the Judkin's technique. Coronary arteries were classi-
fied as normal in the absence of any visible lumen
narrowing at angiography [28].
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systolic pressure was measured in the supine position in
the right arm (brachial artery) and in the posterior tibial
artery of both ankles with an 8-MHz Doppler probe.
The ABI was calculated by dividing the systolic blood
pressure in the ankle by the systolic blood pressure in
the arm.
Laboratory analyses
Venous blood samples were collected after an overnight
fast of 12 h before ultrasound was performed, and
laboratory measurements were performed from fresh
serum samples, as described previously [29]. Patients
with diabetes did not take their antidiabetic oral medica-
tion before the blood sample was drawn. Oral glucose
tolerance tests were performed and postchallenge glu-
cose was measured as plasma glucose at 2 hours after an
oral 75 gram glucose load in individuals without known
diabetes. Serum triglycerides, total cholesterol, low density
lipoprotein (LDL) cholesterol, HDL cholesterol, apolipo-
protein B, apolipoprotein A1, CRP, and plasma glucose
were determined on a Cobas Integra 800® (Roche, Basel,
Switzerland). Haemoglobin A1c (HbA1c) was determined
by high-performance liquid chromatography on an AD-
AMS A1c HA-8160® (Menarini, Florenz, Italy). Plasma
insulin was measured with a Roche Cobas E601® (Roche,
Basel, Switzerland). HOMA index was calculated by
the formula fasting insulin [μU/ml] × fasting glucose
[mg/dl] / 405 [30].
Statistical analysis
Differences in patient characteristics were tested for statis-
tical significance with the Chi square test for categorical
variables; the Mann–Whitney–U and Kruskal–Wallis tests
were used for continuous variables, as appropriate. Spear-
man rank correlation coefficients were calculated. To test
for independent determinants of continuous variables,
analysis of covariance (ANCOVA) was performed, using a
general linear model approach. Results are given as mean ±
standard deviation if not denoted otherwise. Two-sided
p-values <0.05 were considered significant. Sample size
calculations showed that assuming a standard deviation
of 1.5 times the population mean, 190 patients would be
needed per study group to detect a between–group
difference of HOMA insulin resistance scores of 20%
with a power of 80% at an alpha-fault of 0.05. Statistical
analyses were performed with the software package
SPSS 16.0 for Windows (SPSS, Inc., Chicago, IL).
Results
Patient characteristics
Among our 214 PAD patients, there was a preponder-
ance of male gender (73.4%), and a very high preva-
lence of T2DM (40.7%), hypertension (87.9%), andsmoking (84.6%). From our PAD patients, 53.8% had
an ABI ≤0.9 and 46.2% had an ABI ≤0.5. In the control
group (n = 197), there was a preponderance of female
gender (62.9%), as well as a lower prevalence of type 2
diabetes (22.8%), hypertension (74.6%), and smoking
(50.3%) when compared to the PAD patients.
Overall, 112 (27.3%) subjects had the MetS as defined
by NCEP-ATP-III criteria; considering both the presence
of the MetS (NCEP-ATP-III criteria) and the presence of
PAD, 142 subjects had neither the MetS (ATP-III defin-
ition) nor sonographically proven PAD, 55 had the MetS,
but not sonographically proven PAD, 157 did not have
the MetS but had sonographically proven PAD, and 57
had both, the MetS and sonographically proven PAD.
Table 2 summarizes patient characteristics in these four
groups. Table 1 shows medication use in patients with
PAD and in control subjects and Table 3 shows medica-
tion use in the 4 patient subgroups considering both the
presence of PAD and of the MetS.
Insulin resistance in study groups
HOMA-IR scores were higher in MetS patients (NCEP-
ATP-III criteria) than in subjects without the MetS (5.9 ±
6.2 vs. 2.9 ± 3.9; p<0.001). However, HOMA IR did not
differ significantly between patients with PAD and
controls (4.2 ± 5.4 vs. 3.3 ± 4.3; p = 0.124). When both,
the presence of the MetS and of PAD was considered
(Figure 1), HOMA-IR was significantly higher in patients
with the MetS both among those with PAD (6.1 ± 5.7 vs.
3.6 ± 5.2; p <0.001) and among controls (5.8 ± 6.8 vs.
2.3 ± 1.8; p <0.001), whereas it did not differ significantly
between patients with PAD and controls among patients
with the MetS (5.8 ± 6.8 vs. 6.1 ± 5.7; p = 0.587) nor
among those without the MetS (2.3 ± 1.8 vs. 3.6 ± 5.2;
p = 0.165) (Table 4).
Analysis of covariance (ANCOVA) adjusting for age,
gender, smoking, LDL cholesterol, the glomerular filtra-
tion rate, antidiabetic medication and alcohol consump-
tion concordantly showed that HOMA insulin resistance
was significantly associated with the MetS as diagnosed
by ATP-III criteria (F = 12.5; p = <0.001) but not with
sonographically proven PAD (F = 0.86; p = 0.670).
Exclusion of patients with T2DM
In a subgroup analyses, we excluded subjects with T2DM.
Still, HOMA insulin resistance scores were significantly
higher in patients with MetS than in subjects without
MetS among non-diabetic subjects (4.1 ± 3.0 vs. 2.2 ± 1.6;
p <0.001) but were again not significantly different be-
tween the patients with sonographically proven PAD and
controls (2.6 ± 1.9 vs. ± 2.6 ± 2.1; p = 0.644). Also, when
we only excluded the patients with diabetes who were on
insulin, HOMA insulin resistance scores were significantly
higher in patients with the MetS than in subjects without
Table 2 Patient characteristics in subgroups with respect to both the presence of peripheral artery disease and the
presence of the metabolic syndrome
PAD+/MetS+ (n = 57) PAD+/MetS- (n = 157) PAD-/MetS+ (n = 55) PAD-/MetS- (n = 142) p-value
Age (years) 64.9 ± 10 67.5 ± 10 62.7 ± 12 60.8 ± 10 <0.001
Male gender (%) 70.2 74.5 34.5 38.0 <0.001
BMI (kg/m2) 30.1 ± 5 25.9 ± 4 27.7 ± 4 28.8 ± 6 <0.001
Waist-to-hip ratio 1.0 ± 0.8 0.9 ± 0.8 1.0 ± 0.6 0.9 ± 0.7 <0.001
Waist circumference (m) 108.2 ± 11 97.9 ± 12 107.9 ± 10 95.3 ± 13 <0.001
Hypertension (%) 96.5 78.3 52.7 59.9 <0.001
Smoking (%) 84.2 84.7 47.3 51.4 <0.001
Type 2 Diabetes (%) 68.4 30.6 40.0 16.2 <0.001
Total cholesterol (mg/dl) 180.6 ± 46 180.1 ± 41 197.6 ± 50 202.9 ± 45 <0.001
LDL cholesterol (mg/dl) 107.6 ± 41 109.6 ± 37 133.7 ± 42 131.9 ± 39 <0.001
HDL cholesterol (mg/dl) 44.5 ± 15 54.5 ± 16 49.8 ± 15 64.5 ± 20 <0.001
Triglycerides (mg/dl) 218.4 ± 142 129.1 ± 79 197.5 ± 99 115.7 ± 70 <0.001
Fasting glucose (mg/dl) 144.6 ± 68 103.4 ± 27 133.9 ± 61 96.7 ± 22 <0.001
Fasting insulin (μU/ml) 17.1 ± 11 13.1 ± 16 16.9 ±13 9.3 ± 6 <0.001
Postchallenge glucose (mg/dl) 205.1 ± 94 132.9 ± 53 113.5 ± 53 130.3 ± 72 <0.001
HbA1c (DCCT) (%) 7.3 ± 2 5.9 ± 0.8 6.6 ± 2 5.7 ± 0.7 <0.001
HbA1c (IFCC) (mmol/mol) 56 ± 2 41 ± 15 49 ± 2 39 ± 16 <0.001
Apolipoprotein A1 (mg/dl) 147.3 ± 34 158.1 ± 35 146.5 ± 26 164.7 ± 32 <0.001
Apolipoprotein B (mg/dl) 85.5 ± 11 77.6 ± 21 92.3 ± 26 82.8 ± 22 <0.001
CRP (mg/dl) 1.3 ± 3 0.9 ± 2 0.4 ± 0.5 0.3 ± 0.5 <0.001
Leukocytes (109/l) 7.3 ± 2 7.4 ± 2 6.4 ± 2 6.6 ± 2 0.001
Systolic blood pressure (mmHg) 151.1 ± 21 140.0 ± 21 140.5 ± 14 131.1 ± 19 <0.001
Diastolic blood pressure (mmHg) 84.3 ± 11 78.2 ± 12 86.1 ± 8 80.3 ± 9 <0.001
BMI denotes body mass index, LDL low density lipoprotein, HDL high density lipoprotein, MetS metabolic syndrome and PAD peripheral artery disease;
postchallenge glucose is plasma glucose at 2 h after an oral 75 g glucose load. To convert values for fasting plasma glucose to mmol/l multiply by 0.0555, to
convert values for triglycerides to mmol/l multiply by 0.0113 and to convert total cholesterol, LDL cholesterol, or HDL cholesterol to mmol/l multiply by 0.0259;
p-values are given for the all overall difference between study groups.
Table 3 Medication use in subgroups with respect to both the presence of peripheral artery disease and the presence










Aspirin (%) 67.9 67.8 58.2 52.8 0.006
Clopidogrel (%) 26.8 31.1 3.6 4.9 <0.001
Metformin (%) * 30.3 5.1 9.1 5.6 0.007
Sulfonyrea (%) * 24.2 3.4 3.6 5.6 0.050
Glitazone (%) * 6.1 0.9 0.0 0.0 0.011
Insulin (%) * 15.2 10.3 3.6 5.6 0.040
Statins (%) 75.0 69.2 21.8 28.2 0.003
Angiotensin Converting Enzyme Inhibitors (%) 49.1 40.1 24.5 23.9 <0.001
Calcium Antagonists (%) 36.8 29.3 10.9 8.5 <0.001
Beta Adrenoreceptor Blocking Agents (%) 31.6 40.1 61.8 38.0 0.459
Angiotensin II Receptor Blocking Agents (%) 12.3 10.8 9.1 4.9 0.042
PAD denotes peripheral artery disease.
* Percentage of subjects with type 2 diabetes (n = 87 and 45 in the PAD and in the control group, respectively).
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Figure 1 HOMA insulin resistance scores in subgroups. Graph
shows mean values together with standard deviations. PAD denotes
peripheral arterial disease; MetS metabolic syndrome; HOMA
homeostasis model assessment.
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again not significantly different between the patients
with sonographically proven PAD and controls (2.7 ± 1.5
vs. 2.6 ± 2.0; p = 0.599).
IDF definition of the MetS
The prevalence of the MetS according to the IDF defin-
ition was 38.7%. Considering both the IDF MetS and the
presence of sonographically proven PAD, 129 patients
had neither the IDF MetS nor sonographically proven
PAD, 68 had the MetS, but not sonographically proven
PAD, 123 did not have the MetS but had sonographically
proven PAD, and 91 had both, the MetS according to
IDF criteria and sonographically proven PAD.
As with the NCEP-ATP-III definition of the MetS,
HOMA insulin resistance was significantly higher in
patients with the IDF MetS than in subjects who did not
have the IDF MetS in the total study population (5.5 ±
5.9 vs. 2.7 ± 3.7; p <0.001) and both among patients
with sonographically proven PAD (5.6 ± 5.5 vs.3.2 ± 5.2;
p < 0.001) and in the subgroup of control subjects (5.4 ±
6.4 vs. 2.2 ± 1.5; p <0.001), whereas HOMA insulin resist-
ance did not differ significantly between patients with
sonographically proven PAD and control subjects bothTable 4 HOMA insulin resistance in subgroups
PAD + Controls
MetS + 6.1 ± 5.7 5.8 ± 6.8
MetS - 3.6 ± 5.2 2.3 ± 1.8
MetS denotes metabolic syndrome.
PAD denotes peripheral arterial disease.among patients without the IDF MetS (p = 0.442) and
among patients who had the MetS according to IDF
criteria (p = 0.576).
Discussion
From our results we conclude that insulin resistance as
assessed by the HOMA index is significantly associated
with the MetS but is not directly linked to sonographically
determined peripheral atherosclerosis.
Insulin resistance, the metabolic syndrome, and
peripheral arterial disease: what this study contributes to
the literature
Insulin resistance pathophysiologically is the key feature
of the MetS, and correlations between HOMA insulin
resistance and the MetS as a clinical entity have been
described in numerous previous investigations [9,10,31],
whereas the syndrome according to most definitions is
diagnosed as a clinical category in the presence of MetS
stigmata other than insulin resistance scores. We had
published on this important issue previously [8]. Insulin
resistance is a complex and multifaceted disorder which
is extensively addressed in current biomedical research.
Muneyuki et al. [32] for example showed in a small
cohort after adjusting for BMI that low serum amylase
was associated with decreased basal insulin levels and
high insulin resistance. Another investigation by Snoer
et al. [33] found that there is an association between in-
sulin resistance, reduced exercise tolerance and reduced
coronary flow reserve in heart failure patients. Further
to the results of earlier studies [17,34] we demonstrate
the association of insulin resistance with the clinical en-
tity of the MetS and with the individual MetS stigmata
among patients with PAD, a population of a particular
clinical interest.
The key finding of our investigation, however, is that
insulin resistance is not associated with sonographically
proven peripheral atherosclerosis. Hardly any data are
available from the literature on the association between
insulin resistance and PAD. Indeed, only two previous
investigations, one of them by Pande et al. [35] had
addressed this association; however, these studies dif-
fered in important aspects from our investigation. Pande
et al. investigated the general population and used the
ABI instead of ultrasound to diagnose PAD. The men-
tioned second study by Britton et al. [36] also used the
ABI together with a definition of "clinical PAD" based
on patient history and physical examination. Theses
authors described a weak but significant link between
PAD and insulin resistance. However, it is important to
consider that the direct visualization of atherosclerosis
may reflect other features of the development of PAD
than measurement of ABI or other non-visualised PAD
features. Thus, both patient selection and perhaps even
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tributed to the divergence of our findings with the work
reported by Panda [35] and Britton [36].
Our work is the first report on the association between
insulin resistance and PAD using peripheral artery sonog-
raphy. Most importantly, our study, as evidenced by sam-
ple size calculation, was adequately powered to firmly
support also a negative finding. Thus, our investigation for
the first time firmly establishes that there is no association
between insulin resistance and sonographically proven
peripheral atherosclerosis.
The possibility should be considered that the high
prevalence of smoking observed in our cohort may have
overwhelmed the impact of other risk factors. Whatsoever,
because a high smoking prevalence is typical for cohorts
of PAD patients, the high smoking prevalence in our study
population of consecutive, unselected PAD patients re-
flects what is current clinical reality. As we have published
earlier, impaired kidney function is an important indicator
of elevated cardiovascular risk [37]; however, our results
were confirmed after adjustment for the estimated glom-
erular filtration rate.
Strengths and limitations
Important strengths of our study are the direct
visualization of peripheral atherosclerosis by sonog-
raphy, the adequate size of the study population, and
the meticulous characterization of study subjects. Be-
cause the patients were recruited consecutively, the
studied patient sample mirrors the real world scenario
of a typical large angiology outpatient clinic. Of course
we cannot exclude that this patient sample differs e.g.
from PAD patients who are cared for in private practice
or who are hospitalized.
We acknowledge the limitation that because of our
cross-sectional study design the causality of relationships
between parameters cannot be proven; a future study that
longitudinally addresses the association of insulin resist-
ance with the progression of sonographically proven ath-
erosclerosis therefore will be of great interest. Further,
there are limitations of the HOMA technique to measure
insulin resistance. The HOMA index on the one hand is a
firmly established measure of insulin resistance which is
typically applied in large scale epidemiological studies and
therefore guarantees the comparability of our study results
with the data from the literature. However, on the other
hand HOMA is rarely used for clinical decision making
and, more importantly, it should be considered that
HOMA insulin resistance scores like all established
markers of insulin resistance are based on the estimation
of insulin effects on glucose metabolism which of course
do not optimally reflect the much broader metabolic con-
sequences of insulin resistance, e.g. for lipid metabolism.
Future research aiming at the investigation of insulinresistance over and above the insulin-glucose axis there-
fore is necessary.
Conclusions
In conclusion, with respect to HOMA insulin resistance,
our study clearly shows the lack of an association between
insulin resistance and sonographically proven PAD. To-
gether with our previous observation, that insulin resist-
ance is not associated with coronary atherosclerosis [13],
our findings suggest that it may play a more important
role in the thrombotic features of atherothrombotic dis-
ease (which eventually precipitate the clinical cardiovascu-
lar event) than in the development of atherosclerosis
(which is visualized by sonography or angiography).
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